NasdaqGS:BRKR

Stock Analysis Report

Executive Summary

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.

Snowflake

Fundamentals

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has Bruker's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.6%

NasdaqGS:BRKR

-5.3%

US Life Sciences

0.8%

US Market


1 Year Return

69.9%

NasdaqGS:BRKR

23.3%

US Life Sciences

4.8%

US Market

BRKR outperformed the Life Sciences industry which returned 23.3% over the past year.

BRKR outperformed the Market in United States of America which returned 4.7% over the past year.


Share holder returns

BRKRIndustryMarket
7 Day-3.6%-5.3%0.8%
30 Day7.9%1.2%4.3%
90 Day24.3%1.3%2.8%
1 Year70.7%69.9%23.6%23.3%7.1%4.8%
3 Year102.3%99.0%84.6%83.1%47.6%37.9%
5 Year113.9%109.8%122.8%112.2%61.5%43.5%

Price Volatility Vs. Market

How volatile is Bruker's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bruker undervalued based on future cash flows and its price relative to the stock market?

41.9x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Bruker's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Bruker's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Bruker is overvalued based on earnings compared to the US Life Sciences industry average.

Bruker is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Bruker is poor value based on expected growth next year.


Price Based on Value of Assets

Bruker is overvalued based on assets compared to the US Life Sciences industry average.


Next Steps

Future Growth

How is Bruker expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

18.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Bruker's revenue is expected to grow by 5.1% yearly, however this is not considered high growth (20% yearly).

Bruker's earnings are expected to grow by 18.1% yearly, however this is not considered high growth (20% yearly).

Bruker's revenue growth is positive but not above the United States of America market average.

Bruker's earnings growth is expected to exceed the United States of America market average.

Bruker's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Bruker is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).


Next Steps

Past Performance

How has Bruker performed over the past 5 years?

16.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bruker's year on year earnings growth rate has been positive over the past 5 years.

Bruker's 1-year earnings growth exceeds its 5-year average (118.5% vs 16%)

Bruker's earnings growth has exceeded the US Life Sciences industry average in the past year (118.5% vs 45.3%).


Return on Equity

Bruker has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Bruker used its assets more efficiently than the US Life Sciences industry average last year based on Return on Assets.


Return on Capital Employed

Bruker has improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Bruker's financial position?


Financial Position Analysis

Bruker is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Bruker's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Bruker's level of debt (35.5%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (40.9% vs 35.5% today).

Debt is well covered by operating cash flow (62.8%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 25.1x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4x debt.


Next Steps

Dividend

What is Bruker's current dividend yield, its reliability and sustainability?

0.32%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Bruker's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.41%).

Bruker's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

Bruker is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

Bruker is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of Bruker's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of Bruker's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Bruker's salary, the management and board of directors tenure and is there insider trading?

7.9yrs

Average management tenure


CEO

Frank Laukien (59yo)

28.4yrs

Tenure

US$4,479,899

Compensation

Dr. Frank H. Laukien, Ph.D., has been the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Executi ...


CEO Compensation Analysis

Frank's remuneration is lower than average for companies of similar size in United States of America.

Frank's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

7.9yrs

Average Tenure

61yo

Average Age

The average tenure for the Bruker management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.2yrs

Average Tenure

61.5yo

Average Age

The tenure for the Bruker board of directors is about average.


Insider Trading

Bruker individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$16,591,20003 Jun 19
Frank Laukien
EntityIndividual
Role
Chairman
Chairman of the Board
Shares400,000
Max PriceUS$41.48
SellUS$16,591,54131 May 19
Frank Laukien
EntityIndividual
Role
Chairman
Chairman of the Board
Shares400,000
Max PriceUS$42.31
SellUS$57,41317 May 19
Marc Kastner
EntityIndividual
Role
Member of the Board of Directors
Shares1,374
Max PriceUS$41.79

Ownership Breakdown


Management Team

  • Stacey Desrochers

    Treasurer & Director of Investor Relations

  • Gerald Herman (61yo)

    CFO, VP & Corporate Controller

    • Tenure: 1.3yrs
    • Compensation: $1.12m
  • Juergen Srega (64yo)

    President of Bruker CALID Group & Bruker Daltonics Division

    • Tenure: 6.5yrs
    • Compensation: $1.39m
  • Miroslava Minkova

    Director of Investor Relations & Corporate Development

  • Frank Laukien (59yo)

    Chairman

    • Tenure: 28.4yrs
    • Compensation: $4.48m
  • Falko Busse (52yo)

    Executive Officer

    • Tenure: 1.2yrs
    • Compensation: $1.38m
  • Richard Stein (67yo)

    Secretary

    • Tenure: 19.5yrs
    • Compensation: $16.00k
  • Collin D’Silva (62yo)

    President of Chemical Analysis Division

    • Tenure: 9.3yrs
    • Compensation: $1.10m
  • Mark Munch (57yo)

    Executive VP and President of Bruker Nano Group & Bruker Nano Surfaces Division

    • Tenure: 4.0yrs
    • Compensation: $1.82m
  • Urban Faeh

    President of Bruker Optics Division

    • Tenure: 9.5yrs

Board Members

  • William Linton (71yo)

    Lead Director

    • Tenure: 15.3yrs
    • Compensation: $198.03k
  • Cynthia Friend (64yo)

    Director

    • Tenure: 3.2yrs
    • Compensation: $190.15k
  • Marc Kastner (73yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: $191.87k
  • Adelene Perkins (59yo)

    Director

    • Tenure: 2.2yrs
    • Compensation: $200.78k
  • Gilles Martin (56yo)

    Director

    • Tenure: 5.5yrs
    • Compensation: $185.03k
  • Frank Laukien (59yo)

    Chairman

    • Tenure: 28.4yrs
    • Compensation: $4.48m
  • Bob Rosenthal (62yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: $203.03k
  • Richard Packer (61yo)

    Independent Director

    • Tenure: 12.2yrs
    • Compensation: $215.60k
  • Hermann Requardt (64yo)

    Director

    • Tenure: 3.9yrs
    • Compensation: $193.03k
  • John Ornell (61yo)

    Director

    • Tenure: 3.9yrs
    • Compensation: $218.03k

Company Information

Bruker Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bruker Corporation
  • Ticker: BRKR
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: life sciences tools and services
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$7.708b
  • Shares outstanding: 156.79m
  • Website: Click here

Number of Employees


Location

  • Bruker Corporation
  • 40 Manning Road
  • Billerica
  • Massachusetts
  • 1821
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BRKRNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDAug 2000
BKDDB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2000
BRKR *BMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNAug 2000

Biography

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/14 23:33
End of Day Share Price2019/07/12 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.